Mundil, D., Cameron-Vendrig, A
Our clients have reported not only significant weight loss but also improvements in their overall health, increased energy levels, and a boost in self-confidence
As a result, coverage of GLP-1 drugs for the treatment of obesity remains optional for states, while coverage is required for drugs approved for the treatment of diabetes and, since March 2024 and December 2024, for the treatment of cardiovascular disease (Wegovy) and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound), respectively (Table 1)
Timing your GLP-1 injection around meals One of the most common questions researchers ask is whether they should time their injection relative to meals
Following this, participants were given a 10-minute break, completed subjective questionnaires about their current state and experience, including Visual Analogue Scales (VAS) as described above
Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV, et al
